Drug Research
Heraeus completes multi-million Euro cancer therapy API capacity expansion
Heraeus Pharmaceutical Ingredients’ additional production line for Platinum-based highly potent active pharmaceutical ingredients (Pt hAPIs) is now fully operational at the company’s headquarters in Hanau, Germany.
Heraeus, a business line of Heraeus Precious Metals, is the leading global market supplier...
Drug Research
Next Generation Automation Lab Achieves Huge Productivity Gains
Eli Lilly and Company and their industry partners, including sample management specialists – Ziath, are speeding the discovery of new medicines through the fully automated Lilly Life Sciences Studio (L2S2) lab in San Diego, USA.
L2S2 was set up as...
Drug Research
Takeda and Frazier Healthcare Announce Collaboration to Launch HilleVax to Develop Clinical Stage Norovirus Vaccine Candidate
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and...
Drug Research
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and...
Drug Research
Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., announced they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal pipeline...
Drug Research
Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers
Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics have announced their partnership to support biosimilar development...
Drug Research
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471
Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read